The CuraVac Independent Advisory Board is composed of key specialist from the industry or the academic world who help CuraVac management team in its strategic decisions with their valuable input.
Dr. Didier Hoch, M.D.
Dr. Didier Hoch is the CEO of BIOVISION, the World Life Sciences Forum. He is a medical doctor and has more than 25 years’ experience in the pharmaceutical and vaccine industries. From 2000 to 2010, he was at the head of Sanofi Pasteur MSD, vaccine market leader, responsible for the development and distribution of several vaccines, most notably Gardasil. From 2003 to 2009, he was the chairman of the European Vaccine Manufacturer Association (EVM).
Since 2009, Didier Hoch has been the chair of the Health and Science Committee of MEDEF and he is a member of the board of several biotech companies.
Dr. Jean-Paul Prieels, Ph.D.
Dr. Jean-Paul Prieels, Ph.D, served as a Senior Vice President of Research and Development at GlaxoSmithKline Biologicals (now GSK Vaccines) until January 2011. Dr. Prieels joined GlaxoSmithKline Biologicals in 1987 as an Associate Director R&D Projects Evaluation. His responsibilities gradually expanded to lead the global vaccine R&D development activities in Rixensart, Belgium. His career spans from basic research to process and product development. He was instrumental in developing several commercially available vaccines, such as rotavirus, human papilloma virus (HPV), pneumococcal conjugates and others. He served as Head of Research at GSK Vaccines.
He serves as a Director of Vaximm AG. Since 2007, he has been a Member of the Scientific Advisory Board of the Singapore Bioprocessing Technology Institute. He serves as Chairman of the Board at Immune Health and he was also a Board member of Henogen from 2000 to 2008.
Prof. Dr. Marc De Baets, M.D., Ph.D.
Prof. Dr. Marc De Baets is experienced in the clinical management of MG patients and research in the MG field. He is working at the neurology clinic of Maastricht University Hospital where he sees 15 MG patients each week (600 patient contacts per year). Together with Prof Maessen, thoracic surgeon, he coordinates the Robotic Thymectomy Program for The Netherlands. The MUMC has performed more than 150 thymectomies in MG patients. His team has produced fully human anti-human AChR antibodies and non-pathogenic variants for testing in non-human primates. He has also successfully treated EAMG with gene transfer using non-viral methods (in vivo electrotransfer into muscle) and has developed recombinant human competitor antibodies in animal MG models.
Dr. Bruce Forrest, M.D., MBA
Dr. Forrest brings to the company over 25 years of global leadership in pharmaceutical development with specialty expertise in vaccines and biopharmaceuticals development in both major and emerging markets. Dr. Forrest possesses extensive experience and field knowledge of the pharmaceutical development environment in Asia, especially Japan, where he served as Board Member, Corporate Officer and Head of R&D for Wyeth K.K. In this role at Wyeth he oversaw local registrations and approvals of numerous vaccines and therapeutics including pneumococcal conjugate vaccine and tigecycline, and was responsible for overall development activities across East Asia. As a Senior Vice President at Wyeth Pharmaceuticals Dr. Forrest was responsible for all late phase development and manufacturing activities in vaccines including its live attenuated influenza vaccine. Dr. Forrest received a MB/BS and an MD from the University of Adelaide School of Medicine, and an MBA from the University of Warwick-UK.